Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DiscovHER PAN-206 zanidatamab in previously treated HER2-expressing solid tumors
2024-516551-41-00Phase 2Authorised
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Mar 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label trial of zanidatamab in Nonhematologic neoplasms, breast cancer, gastroesophageal junction adenocarcinoma and 2 more (3 cohorts), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Confirmed objective response rate. Planned start Mar 2026; status: authorised.
02
Drugs
zanidatamab
03
Conditions
Nonhematologic neoplasmsbreast cancergastroesophageal junction adenocarcinomacolorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-516551-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516551-41-00.